CNBC September 25, 2024
Key Points
– Novo Nordisk’s blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, according to a new study.
– The results suggest semaglutide, the active ingredient in Ozempic, could potentially become a new alternative treatment for opioid use disorder, which could help address the ongoing opioid epidemic.
– The data adds to growing evidence that a highly popular class of diabetes and obesity treatments called GLP-1s may have health benefits beyond regulating blood sugar and promoting weight loss.
Novo Nordisk‘s blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, demonstrating its potential as an alternative treatment for opioid use disorder, according to a new study released Wednesday.
The...
Today's Sponsors
Today's Sponsor